Kyle Lefkoff is a venture capital investor at Boulder Ventures who has spent nearly four decades treating serious alpinism and venture investing as parallel crafts, applying the same risk management and decision-making skills he uses as a mountain guide to helping founders navigate high-consequence business environments. He co-founded and chaired Array BioPharma from 1998 through its FDA approval and eventual $11.8 billion acquisition by Pfizer, while maintaining a philosophy of pointing credit toward others and focusing on durability and realized returns rather than quick wins or paper marks. Kyle Lefkoff is a venture capital investor at Boulder Ventures who has spent nearly four decades treating serious alpinism and venture investing as parallel crafts, applying the same risk management and decision-making skills he uses as a mountain guide to helping founders navigate high-consequence business environments. He co-founded and chaired Array BioPharma from 1998 through its FDA approval and eventual $11.8 billion acquisition by Pfizer, while maintaining a philosophy of pointing credit toward others and focusing on durability and realized returns rather than quick wins or paper marks.